BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31090597)

  • 1. Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy.
    Yenigürbüz FD; Kızmazoğlu D; Ateş H; Erdem M; Tüfekçi Ö; Yılmaz Ş; Ören H
    Blood Coagul Fibrinolysis; 2019 Jun; 30(4):149-155. PubMed ID: 31090597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
    Eguiguren JM; Pui CH
    Med Pediatr Oncol; 1992; 20(1):58-60. PubMed ID: 1727213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
    Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
    Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.
    Chaturvedi S; Cockrell E; Espinola R; Hsi L; Fulton S; Khan M; Li L; Fonseca F; Kundu S; McCrae KR
    Thromb Res; 2015 Jan; 135(1):102-8. PubMed ID: 25467081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
    Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine.
    Pui CH; Jackson CW; Chesney C; Lyles SA; Bowman WP; Abromowitch M; Simone JV
    J Clin Oncol; 1983 Jun; 1(6):380-5. PubMed ID: 6583320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
    Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
    Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of BFM-90 program in the treatment of acute lymphoblastic leukemia in children in the studies of Polish pediatric leukemia/lymphoma group].
    Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Juszczak K; Armata J; Balcerska A; Balwierz W; Bubała H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Lukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sońta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
    Wiad Lek; 1998; 51 Suppl 4():25-32. PubMed ID: 10731940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy.
    Çankal A; Tüfekçi Ö; Gözmen S; Yüksel F; Vergin C; Irken G; Ören H
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):375-80. PubMed ID: 23337707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.